Julian D. Gillmore
Alnylam Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Amyloidosis: Diagnosis, Treatment, Outcomes, Parathyroid Disorders and Treatments, Neuroendocrine Tumor Research Advances, Protein Kinase Regulation and GTPase Signaling, Peptidase Inhibition and Analysis
Most-Cited Works
- → Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis(2016)1,939 cited
- → CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis(2021)1,558 cited
- → Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases(2021)1,093 cited
- → Systemic amyloidosis(2015)972 cited
- → A new staging system for cardiac transthyretin amyloidosis(2017)713 cited
- → Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis(2002)683 cited
- → Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis